Abstract
Therapeutic benefit of adjuvant active specific immunotherapy (A.S.I.) with autologous tumor-vaccines in patients with colon cancer. Results of a randomised fase III study
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
